Nasus Pharma Ltd (NSRX) stock
NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
$2.87+0.05 (+1.77%)
Close on Nov 13, 2026Market cap $25.87MP/E –Yield –
Nasus Pharma r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $2.24M, up 567.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.24M | +567.8% |
| FY2024 | Dec 31, 2024 | $335.00K | -40.9% |
| FY2023 | Dec 31, 2023 | $567.00K | – |
See a number that looks wrong?